US +1 (713) 559-7900 Europe +44 (0) 1344 891121 info@pharm-olam.com Grass & Birch Allergy Phase II Parallel Studies Pharm-Olam was contracted to provide a full-service solution for two Phase II, dose escalation allergy studies that required a total of 500 patients in Europe and were ran in parallel. With two different indications required, Grass Pollen Allergy and Birch Pollen Allergy, Pharm-Olam completed a comprehensive feasibility program and presented the findings to the sponsor for analysis and approval. Once approved, Pharm-Olam committed to recruit the required patients within 4 months, while adhering to strict inclusion and exclusion criteria. Allergy Case Study | PRESENTED BY PHARM-OLAM Enrollment Period Contracted = 4 months Actual = 2.5 months Study Timeline Snaps

Join for free to read